NCT01998464

Brief Summary

Retinal vasculitis is a sight-threatening inflammation that involves the blood vessels of the retina, the tissue that lines the inside of the eye. This inflammation may occur on its own or as a result of an infectious, cancerous, or inflammatory disorder. Optical coherence tomography (OCT) is an imaging technology that can perform non-contact cross-sectional imaging of retinal and choroidal tissue structure in real time. It is similar to ultrasound imaging, except that OCT measures the intensity of reflected light rather than sound waves. The purpose of this study is to see if non-invasive OCT technology can diagnose retinal vasculitis as well as the more invasive fluorescein angiography, which requires an injection of dye into the vein of an arm of a patient. The study will also compare the mapping of blood vessels (angiography) and loss of blood flow (ischemia) by fluorescein angiography and OCT.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
12

participants targeted

Target at below P25 for all trials

Timeline
Completed

Started Jan 2014

Longer than P75 for all trials

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

November 18, 2013

Completed
11 days until next milestone

First Posted

Study publicly available on registry

November 29, 2013

Completed
1 month until next milestone

Study Start

First participant enrolled

January 1, 2014

Completed
4.6 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

August 23, 2018

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

August 23, 2018

Completed
Last Updated

February 12, 2024

Status Verified

February 1, 2024

Enrollment Period

4.6 years

First QC Date

November 18, 2013

Last Update Submit

February 8, 2024

Conditions

Keywords

Retinal VasculitisOptical coherence tomographyOCTImaging

Outcome Measures

Primary Outcomes (1)

  • Blood flow patterns in retinal vasculitis

    To determine if identifying early changes in blood vessel patterns will aid in early diagnosis and treatment of retinal vasculitis. Total retinal blood flow will be measured in uL/min.

    24 months

Secondary Outcomes (1)

  • Ischemia in retinal vasculitis

    24 months

Study Arms (1)

Retinal Vasculitis Group

Up to 35 patients diagnosed with retinal vasculitis will be considered and evaluated for enrollment in this study.

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodProbability Sample
Study Population

This study will measure blood vessel pattern/flow changes in up to 35 patients with retinal vasculitis.

You may qualify if:

  • Diagnosis of retinal vasculitis

You may not qualify if:

  • Inability to give informed consent.
  • Inability to complete the qualifying study tests within a 30 day period from date of enrollment
  • Significant renal disease, defined as a history of chronic renal failure requiring dialysis or kidney transplant.
  • A prior history of reaction to fluorescein or other dyes.
  • A condition that, in the opinion of the investigator, would preclude participation in the study (e.g. unstable medical status including blood pressure, cardiovascular disease, and glycemic control).
  • Blood pressure \> 180/110 (systolic above 180 OR diastolic above 110). If blood pressure is brought below 180/110 by anti-hypertensive treatment, subject can become eligible.
  • Systemic anti-vascular endothelial growth factor (VEGF) or pro-VEGF treatment within 4 months prior to treatment.
  • Women of child-bearing potential: pregnant or lactating or intending to become pregnant within the next 12 months due to unknown safety of fluorescein angiography.
  • Prior panretinal photocoagulation (PRP) or focal laser that would alter the macular perfusion and retinovascular features.
  • Inability to maintain stable fixation for OCT imaging.
  • Other ocular condition is present such that, in the opinion of the investigator, may alter the retinal perfusion.
  • An ocular condition is present that, in the opinion of the investigator, might affect or alter visual acuity during the course of the study (i.e. cataract)
  • Substantial cataract that, in the opinion of the investigator, is likely to decrease visual acuity by 3 lines or more (i.e. cataract would be reducing acuity to 20/40 or worse if the eye was otherwise normal).
  • Media opacity or otherwise that would prevent either fixation or ability to obtain adequate images as determined by the examiner.
  • History of major ocular surgery (including vitrectomy, cataract extraction, scleral buckle, any intraocular surgery, etc) within prior 4 months.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

OHSU

Portland, Oregon, 97239, United States

Location

MeSH Terms

Conditions

Retinal Vasculitis

Condition Hierarchy (Ancestors)

Retinal DiseasesEye DiseasesVasculitisVascular DiseasesCardiovascular Diseases

Study Officials

  • Phoebe Lin, MD, PhD

    Oregon Health and Science University

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
observational
Observational Model
CASE CONTROL
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Phoebe Lin, MD, PhD, Assistant Professor of Ophthalmology

Study Record Dates

First Submitted

November 18, 2013

First Posted

November 29, 2013

Study Start

January 1, 2014

Primary Completion

August 23, 2018

Study Completion

August 23, 2018

Last Updated

February 12, 2024

Record last verified: 2024-02

Locations